Alyson L Dickson1, Laura L Daniel1, Elise Jackson1, Jacy Zanussi1, Wenjian Yang2, W Dale Plummer3, William D Dupont3, Wei-Qi Wei4, Puran Nepal1, Adriana M Hung1, Nancy J Cox1, Sara L Van Driest5, QiPing Feng1, Jun J Yang2, C Michael Stein1, Jonathan D Mosley6, Cecilia P Chung1. 1. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (A.L.D., L.L.D., E.J., J.Z., P.N., A.M.H., N.J.C., Q.F., C.M.S., C.P.C.). 2. Pharmacy and Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee (W.Y., J.J.Y.). 3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee (W.D.P., W.D.D.). 4. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee (W.W.). 5. Departments of Medicine and Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee (S.L.V.). 6. Departments of Medicine and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee (J.D.M.).
Abstract
BACKGROUND: Thiopurines are an important class of immunosuppressants despite their risk for hematopoietic toxicity and narrow therapeutic indices. Benign neutropenia related to an ACKR1 variant (rs2814778-CC) is common among persons of African ancestries. OBJECTIVE: To test whether rs2814778-CC was associated with azathioprine discontinuation attributed to hematopoietic toxicity and lower thiopurine dosing. DESIGN: Retrospective cohort study. SETTING: Two tertiary care centers. PATIENTS: Thiopurine users with White or Black race. MEASUREMENTS: Azathioprine discontinuation attributed to hematopoietic toxicity. Secondary outcomes included weight-adjusted final dose, leukocyte count, and change in leukocyte count. RESULTS: The rate of azathioprine discontinuation attributed to hematopoietic toxicity was 3.92 per 100 person-years among patients with the CC genotype (n = 101) and 1.34 per 100 person-years among those with the TT or TC genotype (n = 1365) (hazard ratio [HR] from competing-risk model, 2.92 [95% CI, 1.57 to 5.41]). The risk remained significant after adjustment for race (HR, 2.61 [CI, 1.01 to 6.71]). The risk associated with race alone (HR, 2.13 [CI, 1.21 to 3.75]) was abrogated by adjustment for genotype (HR, 1.13 [CI, 0.48 to 2.69]). Lower last leukocyte count and lower dosing were significant among patients with the CC genotype. Lower dosing was validated in an external cohort of 94 children of African ancestries prescribed the thiopurine 6-mercaptopurine (6-MP) for acute lymphoblastic leukemia. The CC genotype was independently associated with lower 6-MP dose intensity relative to the target daily dose of 75 mg/m2 (median, 0.83 [IQR, 0.70 to 0.94] for the CC genotype vs. 0.94 [IQR, 0.72 to 1.13] for the TT or TC genotype; P = 0.013). LIMITATIONS: Unmeasured confounding; data limited to tertiary centers. CONCLUSION: Patients with the CC genotype had higher risk for azathioprine discontinuation attributed to hematopoietic toxicity and lower thiopurine doses. Genotype was associated with those risks, even after adjustment for race. PRIMARY FUNDING SOURCE: National Institutes of Health.
BACKGROUND: Thiopurines are an important class of immunosuppressants despite their risk for hematopoietic toxicity and narrow therapeutic indices. Benign neutropenia related to an ACKR1 variant (rs2814778-CC) is common among persons of African ancestries. OBJECTIVE: To test whether rs2814778-CC was associated with azathioprine discontinuation attributed to hematopoietic toxicity and lower thiopurine dosing. DESIGN: Retrospective cohort study. SETTING: Two tertiary care centers. PATIENTS: Thiopurine users with White or Black race. MEASUREMENTS: Azathioprine discontinuation attributed to hematopoietic toxicity. Secondary outcomes included weight-adjusted final dose, leukocyte count, and change in leukocyte count. RESULTS: The rate of azathioprine discontinuation attributed to hematopoietic toxicity was 3.92 per 100 person-years among patients with the CC genotype (n = 101) and 1.34 per 100 person-years among those with the TT or TC genotype (n = 1365) (hazard ratio [HR] from competing-risk model, 2.92 [95% CI, 1.57 to 5.41]). The risk remained significant after adjustment for race (HR, 2.61 [CI, 1.01 to 6.71]). The risk associated with race alone (HR, 2.13 [CI, 1.21 to 3.75]) was abrogated by adjustment for genotype (HR, 1.13 [CI, 0.48 to 2.69]). Lower last leukocyte count and lower dosing were significant among patients with the CC genotype. Lower dosing was validated in an external cohort of 94 children of African ancestries prescribed the thiopurine 6-mercaptopurine (6-MP) for acute lymphoblastic leukemia. The CC genotype was independently associated with lower 6-MP dose intensity relative to the target daily dose of 75 mg/m2 (median, 0.83 [IQR, 0.70 to 0.94] for the CC genotype vs. 0.94 [IQR, 0.72 to 1.13] for the TT or TC genotype; P = 0.013). LIMITATIONS: Unmeasured confounding; data limited to tertiary centers. CONCLUSION: Patients with the CC genotype had higher risk for azathioprine discontinuation attributed to hematopoietic toxicity and lower thiopurine doses. Genotype was associated with those risks, even after adjustment for race. PRIMARY FUNDING SOURCE: National Institutes of Health.
Authors: Rahul Lakhotia; Anita Aggarwal; Mary E Link; Griffin P Rodgers; Matthew M Hsieh Journal: Blood Cells Mol Dis Date: 2019-03-15 Impact factor: 3.039
Authors: William Zabala; Raquel Cruz; Manuel Barreiro-de Acosta; María Chaparro; Julián Panes; Ana Echarri; Maria Esteve; Daniel Carpio; Montserrat Andreu; Esther García-Planella; Eugeni Domenech; Angel Carracedo; Javier P Gisbert; Francisco Barros Journal: Pharmacogenomics Date: 2013-04 Impact factor: 2.533
Authors: Alyson L Dickson; Laura L Daniel; Jacy Zanussi; W Dale Plummer; Wei-Qi Wei; Ge Liu; Tyler Reese; Prathima Anandi; Kelly A Birdwell; Vivian Kawai; Nancy J Cox; William D Dupont; Adriana M Hung; QiPing Feng; C Michael Stein; Cecilia P Chung Journal: Clin Pharmacol Ther Date: 2021-10-12 Impact factor: 6.903
Authors: Sophie E Legge; Rune H Christensen; Liselotte Petersen; Antonio F Pardiñas; Matthew Bracher-Smith; Steven Knapper; Jonas Bybjerg-Grauholm; Marie Baekvad-Hansen; David M Hougaard; Thomas Werge; Merete Nordentoft; Preben Bo Mortensen; Michael J Owen; Michael C O'Donovan; Michael E Benros; James T R Walters Journal: Hum Mol Genet Date: 2020-12-18 Impact factor: 6.150